Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02864953
Previous Study | Return to List | Next Study

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02864953
Recruitment Status : Recruiting
First Posted : August 12, 2016
Last Update Posted : August 26, 2021
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:

The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives of Part 1 of the study are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI.

The objectives of Part 2 of the study are to evaluate long-term disability following LHI, to evaluate long-term outcome measures of clinical function, quality of life, and healthcare utilization, and to assess the safety of BIIB093 in subjects with LHI during the follow-up period.


Condition or disease Intervention/treatment Phase
Brain Edema Stroke, Acute Drug: BIIB093 Drug: Placebo Phase 3

Detailed Description:
This study, previously posted by Remedy Pharmaceuticals, Inc., has transitioned to Biogen.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 768 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Actual Study Start Date : August 29, 2018
Estimated Primary Completion Date : December 29, 2023
Estimated Study Completion Date : September 29, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Glyburide

Arm Intervention/treatment
Experimental: BIIB093
BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
Drug: BIIB093
Administered as specified in the treatment arm.
Other Names:
  • glibenclamide
  • glibenclamide intravenous (IV)
  • glyburide
  • CIRARA

Placebo Comparator: Placebo
Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
Drug: Placebo
Administered as specified in the treatment arm.




Primary Outcome Measures :
  1. Part 1: Percentage of Participants with Improvement in Functional Outcome at Day 90 Assessed via the Modified Rankin Scale (mRS) [ Time Frame: Baseline up to Day 90 ]
    mRS is a standardized interview that measures the degree of disability or dependence in the daily activities of people who have suffered causes of neurological disability. The score will be calculated as a 5-category ordinal scale. The 5-category mRS combines mRS categories 0 and 1 and mRS categories 5 and 6 (0/1, 2, 3, 4, 5/6). The mRS ranges from 0 to 6, with higher scores indicating worse outcome.


Secondary Outcome Measures :
  1. Part 1: Time to All-Cause Death [ Time Frame: Baseline up to Day 90 ]
  2. Part 1: Number of Participants Who Achieved mRS 0-4 at Day 90 [ Time Frame: Baseline up to Day 90 ]
    mRS is a standardized interview that measures the degree of disability or dependence in the daily activities of participants who have suffered causes of neurological disability. The score will be calculated as a 5-category ordinal scale. The 5-category mRS combines mRS categories 0 and 1 and mRS categories 5 and 6 (0/1, 2, 3, 4, 5/6). The mRS ranges from 0 to 6, with higher scores indicating worse outcome.

  3. Part 1: Reduction in Midline Shift at 72 Hours [ Time Frame: Baseline up to 72 hours ]
    Midline shift will be assessed by non-contrast computed tomography (NCCT) or MRI.

  4. Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to Day 90 ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.


Other Outcome Measures:
  1. Part 2: mRS Score [ Time Frame: Month 6 and 12 ]
    mRS is a standardized interview that measures the degree of disability or dependence in the daily activities of participants who have suffered causes of neurological disability. The score will be calculated as a 5-category ordinal scale. The 5-category mRS combines mRS categories 0 and 1 and mRS categories 5 and 6 (0/1, 2, 3, 4, 5/6). The mRS ranges from 0 to 6, with higher scores indicating worse outcome.

  2. Part 2: EuroQol 5-Level Assessment of Health Outcomes (EQ-5D-5L) Score [ Time Frame: Month 6 and 12 ]
    The questionnaire of EQ-5D-5L contains 5 dimensions, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and uses a 5-point Likert scale scored from 1 (no problem) to 5 (unable to/extreme problems). The numerical description of 5 dimensions represents the health state and is defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health).

  3. Part 2: Barthel Index (BI) Score [ Time Frame: Month 6 and 12 ]
    BI measures the extent to which somebody can function independently and has mobility in their activities of daily living. It is a 10-item ordinal scale that cover mobility and self-care domains (feeding [0-10], bathing [0-5], grooming [0-5], dressing [0-10], bowel control [0-10], bladder control [0-10], toileting [0-10], chair transfer [0-15], ambulation [0-15], and stair climbing [0-10]). Total score is the sum of individual scores of each item, ranging from 0 (total dependence) to 100 (complete independence).

  4. Part 2: Stroke Impact Scale 16 Questions (SIS-16) Score [ Time Frame: Month 6 and 12 ]
    The SIS-16 is developed to assess physical function in participants with stroke at approximately 1 to 3 months poststroke. It is a subjective questionnaire asked to the participant pertaining of 16 questions. Each question is rated 1-5 and then the scores are totalled. Total scores can range from 16-80 (16 means that none of the functional tasks asked can be performed, a score of 80 means the participant has no issues at all performing any of the tasks asked).

  5. Part 2: Zarit Burden Interview Score [ Time Frame: Month 12 ]
    The interview is developed to measure subjective burden among caregivers of adults with dementia. The 22-item self-report inventory examines burden associated with functional/behavioral impairments and the home care situation. The items are worded subjectively, focusing on the affective response of the caregiver. Scores range from 0 to 88 where lower scores indicate little to no burden. Higher scores indicate greater burden.

  6. Part 2: HealthCare Resource Utilization (HCRU) Questionnaire: Number of Participants With Visits to Healthcare Professionals for Treatment [ Time Frame: Month 12 ]
    HCRU questionnaire will collect data on the healthcare resources used over the course of the study. They are developed to address the need for valid costing estimates of a particular disease state. They are developed to capture the quantity of resources used to extrapolate the overall cost of a disease or impact of an intervention.

  7. Part 2: Number of Participants With SAEs [ Time Frame: Up to Month 12 ]
    A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory.
  2. A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions.
  3. Screening National Institutes of Health Stroke Scale (NIHSS) >=10.
  4. At the time of randomization, and in the Investigator's judgement, it must be feasible for study drug treatment infusion to be initiated no later than 10 hours after time of symptom onset, if known, or the time last known normal.

    • Participants who wake with stroke may be included if neurological and other exclusion criteria are satisfied. The time of stroke onset is to be taken as the midpoint between sleep onset (or last known to be normal) and time of waking. .
  5. For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI.

Exclusion Criteria:

  1. Participant is likely to have supportive care withdrawn on the first day.
  2. Commitment to decompressive craniectomy (DC) prior to enrollment.
  3. Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02864953


Contacts
Layout table for location contacts
Contact: US Biogen Clinical Trial Center 866-633-4636 clinicaltrials@biogen.com
Contact: Global Biogen Clinical Trial Center clinicaltrials@biogen.com

Locations
Hide Hide 255 study locations
Layout table for location information
United States, Arizona
Research Site Recruiting
Phoenix, Arizona, United States, 85013
Research Site Recruiting
Tucson, Arizona, United States, 85724
United States, California
Research Site Recruiting
La Jolla, California, United States, 92023
Research Site Recruiting
Palo Alto, California, United States, 94304
Research Site Recruiting
Sacramento, California, United States, 95817
United States, Colorado
Research SIte Recruiting
Aurora, Colorado, United States, 80045
United States, Connecticut
Research Site Recruiting
New Haven, Connecticut, United States, 06520
United States, Florida
Research Site Recruiting
Gainesville, Florida, United States, 32610
Research Site Active, not recruiting
Jacksonville, Florida, United States, 32207
Research Site Recruiting
Jacksonville, Florida, United States, 32209
Research Site Recruiting
Tampa, Florida, United States, 33606
United States, Georgia
Research Site Recruiting
Atlanta, Georgia, United States, 30303
Research Site Recruiting
Augusta, Georgia, United States, 30912
United States, Hawaii
Research Site Recruiting
Honolulu, Hawaii, United States, 96813
United States, Illinois
Research Site Recruiting
Chicago, Illinois, United States, 60612
United States, Kansas
Research Site Recruiting
Kansas City, Kansas, United States, 64111
Research Site Recruiting
Kansas City, Kansas, United States, 66103
United States, Kentucky
Research Site Recruiting
Louisville, Kentucky, United States, 40202
United States, Louisiana
Research Site Recruiting
New Orleans, Louisiana, United States, 70121
United States, Maine
Research Site Recruiting
Portland, Maine, United States, 04102
United States, Maryland
Research Site Recruiting
Baltimore, Maryland, United States, 21201
Research Site Recruiting
Baltimore, Maryland, United States, 21215
United States, Massachusetts
Research Site Recruiting
Boston, Massachusetts, United States, 02114
Research Site Recruiting
Boston, Massachusetts, United States, 02115
Research Site Recruiting
Boston, Massachusetts, United States, 02218
Research Site Recruiting
Worcester, Massachusetts, United States, 01655
United States, Michigan
Research Site Recruiting
Detroit, Michigan, United States, 48202-2608
Research Site Recruiting
Detroit, Michigan, United States, 48236
United States, Minnesota
Research Site Recruiting
Minneapolis, Minnesota, United States, 55415
United States, Missouri
Research Site Recruiting
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Research Site Recruiting
Edison, New Jersey, United States, 08818
Research Site Active, not recruiting
Neptune, New Jersey, United States, 07753
Research Site Recruiting
New Brunswick, New Jersey, United States, 08901
Research Site Recruiting
Ridgewood, New Jersey, United States, 07451
United States, New Mexico
Research Site Recruiting
Albuquerque, New Mexico, United States, 87106
United States, New York
Research Site Recruiting
Buffalo, New York, United States, 14203
Research Site Recruiting
Manhasset, New York, United States, 11030
Research Site Recruiting
New York, New York, United States, 10003
Research Site Recruiting
New York, New York, United States, 10016
Research Site Recruiting
New York, New York, United States, 10032
Research Site Recruiting
Rochester, New York, United States, 14642
Research Site Recruiting
Syracuse, New York, United States, 13210
United States, North Carolina
Research Site Recruiting
Chapel Hill, North Carolina, United States, 27599-2200
Research Site Active, not recruiting
Durham, North Carolina, United States, 27710
Research Site Recruiting
Greensboro, North Carolina, United States, 27403
Research Site Recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Research Site Recruiting
Akron, Ohio, United States, 44304
Research Site Recruiting
Cincinnati, Ohio, United States, 45219
Research Site Active, not recruiting
Cleveland, Ohio, United States, 44106
Research Site Recruiting
Cleveland, Ohio, United States, 44195
Research Site Recruiting
Columbus, Ohio, United States, 43210
Research Site Recruiting
Dayton, Ohio, United States, 45414
Research Site Recruiting
Toledo, Ohio, United States, 43606
United States, Oklahoma
Research Site Not yet recruiting
Tulsa, Oklahoma, United States, 74104
United States, Oregon
Research Site Recruiting
Portland, Oregon, United States, 97225
Research Site Recruiting
Portland, Oregon, United States, 97239
United States, Pennsylvania
Research Site Active, not recruiting
Allentown, Pennsylvania, United States, 18103
Research Site Recruiting
Hershey, Pennsylvania, United States, 17033
Research Site Recruiting
Philadelphia, Pennsylvania, United States, 119125
Research Site Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Research Site Recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
Research Site Recruiting
Providence, Rhode Island, United States, 02903
United States, Tennessee
Research Site Active, not recruiting
Chattanooga, Tennessee, United States, 37403
Research Site Not yet recruiting
Memphis, Tennessee, United States, 38104
Research Site Recruiting
Nashville, Tennessee, United States, 37207
Research Site Recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
Research SIte Not yet recruiting
Austin, Texas, United States, 78705
Research Site Recruiting
Harlingen, Texas, United States, 78550
United States, Utah
Research Site Recruiting
Salt Lake City, Utah, United States, 84132
United States, Washington
Research Site Recruiting
Seattle, Washington, United States, 98104
United States, Wisconsin
Research SIte Not yet recruiting
Madison, Wisconsin, United States, 53792
Australia, New South Wales
Research Site Recruiting
Liverpool, New South Wales, Australia, 2170
Reseach Site Recruiting
New Lambton Heights, New South Wales, Australia, 2305
Research Site Recruiting
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
Research Site Not yet recruiting
Southport, Queensland, Australia, 4215
Research Site Active, not recruiting
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
Research Site Recruiting
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Research Site Recruiting
Clayton, Victoria, Australia, 3168
Research Site Not yet recruiting
Footscray, Victoria, Australia, 3011
Research Site Recruiting
Melbourne, Victoria, Australia, 3004
Research Site Recruiting
Parkville, Victoria, Australia, 3050
Research Site Recruiting
St Albans, Victoria, Australia, 3021
Belgium
Research Site Recruiting
Gent, Belgium, 9000
Research Site Recruiting
Leuven, Belgium, 3000
Research Site Recruiting
Liege, Belgium, 4000
Research Site Active, not recruiting
Yvoir, Belgium
Brazil
Research Site Recruiting
Fortaleza, Ceará, Brazil, 60155-290
Research Site Not yet recruiting
Campo Largo, Paraná, Brazil, 83606-177
Research Site Recruiting
Porto Alegre, Rio Grande Do Sul, Brazil, 2350
Research Site Recruiting
Joinville, Santa Catarina, Brazil, 89202-165
Research Site Recruiting
Ribeirao Preto, Sao Paulo, Brazil, 3900
Research Site Recruiting
Sao Paulo, Brazil, 715
Canada, Alberta
Research Site Recruiting
Calgary, Alberta, Canada, AB T2N 2T9
Research Site Recruiting
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Research Site Not yet recruiting
Vancouver, British Columbia, Canada
China, Anhui
Research Site Not yet recruiting
Hefei, Anhui, China, 230001
China, Beijing
Research Site Recruiting
Beijing, Beijing, China, 100053
Research Site Recruiting
Beijing, Beijing, China, 100083
China, Bejing
Reseach Site Recruiting
Beijing, Bejing, China, 100070
China, Guangdong
Research SIte Recruiting
Guangzhou, Guangdong, China, 510080
Research Site Recruiting
Guangzhou, Guangdong, China, 510260
China, Hainan
Research Site Recruiting
Haikou, Hainan, China, 570311
China, Hebei
Research Site Not yet recruiting
Shijiazhuang, Hebei, China, 50000
China, Hubei
Research Site Not yet recruiting
Wuhan, Hubei, China, 430030
Research Site Recruiting
Wuhan, Hubei, China, 430060
China, Jiangsushe
Research Site Recruiting
Suzhou, Jiangsushe, China, 215004
China, Jiangsu
Research Site Recruiting
Huai'an, Jiangsu, China, 223300
Research Site Recruiting
Nanjing, Jiangsu, China, 210009
Research Site Recruiting
Nanjing, Jiangsu, China, 210011
Research Site Recruiting
Nantong, Jiangsu, China, 226001
Research Site Recruiting
Xuzhou, Jiangsu, China, 221006
China, Jiangxi
Research Site Recruiting
Nanchang, Jiangxi, China, 330006
Research Site Recruiting
Pingxiang, Jiangxi, China, 337055
China, Jilin
Research Site Not yet recruiting
Changchun, Jilin, China, 130021
China, Shanghai
Research Site Recruiting
Shanghai, Shanghai, China, 200040
China, Shanxi
Research Site Not yet recruiting
Taiyuan, Shanxi, China, 030001
Research Site Not yet recruiting
Xi'an, Shanxi, China, 710004
China, Sichuan
Research Site Recruiting
Chongqing, Sichuan, China, 400042
China, Tianjin
Research Site Recruiting
Tianjin, Tianjin, China, 300052
China, Zhejiang
Research Site Recruiting
Hangzhou, Zhejiang, China, 310016
China
Research Site Not yet recruiting
Shanghai, China, 200001
Research Site Not yet recruiting
Wenzhou, China, 325000
Croatia
Research Site Recruiting
Varazdin, Croatia, 42000
Research Site Not yet recruiting
Zagreb, Croatia, 10000
Research Site Recruiting
Zagreb, Croatia, 10000
Czechia
Research Site Recruiting
Brno, Czechia, 62500
Research Site Recruiting
Brno, Czechia, 656 91
Research Site Recruiting
Hradec Kralove, Czechia, 50333
Research Site Recruiting
Ostrava-Poruba, Czechia, 70800
Research Site Recruiting
Prague, Czechia, 150 06
Research Site Recruiting
Praha, Czechia, 10034
Denmark
Research Site Recruiting
Copenhagen, Denmark, 2400
Research Site Recruiting
Glostrup, Denmark, 2600
Research Site Recruiting
Roskilde, Denmark, 4000
Finland
Research Site Recruiting
Helsinki, Finland, 00290 HUS
Research Site Recruiting
Turku, Finland, 20520
France
Research Site Recruiting
Caen, Calvados, France, 14033
Research Site Recruiting
Besancon, Doubs, France, 25030
Research Site Active, not recruiting
Brest cedex, Finistere, France, 29609
Research Site Recruiting
Bordeaux, Gironde, France, 33076
Research Site Recruiting
Rennes, Ille-et-Vilaine, France, 35000
Research Site Recruiting
Lille Cedex, La Réunion 16, France, 59037
Research Site Recruiting
Nantes cedex 1, Loire Atlantique, France, 44093
Research Site Recruiting
Nancy, Meurthe Et Moselle, France, 54035
Research Site Recruiting
Le Kremlin Bicêtre cedex, Val De Marne, France, 94275
Germany
Research Site Recruiting
Freiburg, Baden Wuerttemberg, Germany, 79106
Research Site Active, not recruiting
Augsburg, Bayern, Germany, 86156
Research Site Recruiting
Bad Neustadt Saale, Bayern, Germany, 97616
Research Site Recruiting
Erlangen, Bayern, Germany, 91054
Research Site Recruiting
Frankfurt, Hessen, Germany, 60528
Research Site Recruiting
Frankfurt, Hessen, Germany, 65929
Research Site Recruiting
Kassel, Hessen, Germany, 34125
Research Site Recruiting
Essen, Nordrhein Westfalen, Germany, 45147
Research Site Recruiting
Muenster, Nordrhein Westfalen, Germany, 48149
Research Site Recruiting
Altenburg, Thueringen, Germany, 04600
Research Site Not yet recruiting
Darmstadt, Germany, 34283
Research Site Recruiting
Dresden, Germany, 1307
Research Site Not yet recruiting
Essen, Germany, 45131
Research Site Active, not recruiting
Jena, Germany, 07747
Hungary
Research Site Recruiting
Budapest, Hungary, 1083
Reserch Site Recruiting
Gyor, Hungary, 9023
Research Site Recruiting
Kaposvar, Hungary, 7400
Research Site Recruiting
Kistarcsa, Hungary, 2143
Research Site Recruiting
Nyiregyhaza, Hungary, 4400
Research Site Recruiting
Szeged, Hungary, 6725
Israel
Research Site Recruiting
Be'er Sheva, Israel, 85025
Research Site Recruiting
Beer Sheva, Israel, 8410101
Research Site Active, not recruiting
Haifa, Israel, 3109601
Research Site Active, not recruiting
Jerusalem, Israel, 9103102
Research Site Active, not recruiting
Jerusalem, Israel, 9112001
Research Site Active, not recruiting
Petah Tikva, Israel, 49100
Research Site Recruiting
Tel Aviv, Israel, 64239
Italy
Research Site Recruiting
Rozzano, Milano, Italy, 20089
Research Site Recruiting
Rome, Roma, Italy, 00133
Research Site Recruiting
Rome, Roma, Italy, 00161
Research Site Recruiting
Rome, Roma, Italy, 00189
Research Site Recruiting
Brescia, Italy, 25123
Research Site Recruiting
Firenze, Italy, 50134
Research Site Recruiting
Genova, Italy, 16132
Research Site Recruiting
Milano, Italy, 20122
Research Site Recruiting
Milano, Italy, 20132
Research Site Recruiting
Milano, Italy, 20162
Research Site Recruiting
Siena, Italy, 53100
Japan
Research Site Recruiting
Toyota-shi, Aichi-Ken, Japan, 471-8513
Research Site Recruiting
Hachinohe-shi, Aomori-Ken, Japan, 039 1104
Research Site Recruiting
Kisarazu, Chiba Prefecture, Japan, 292-8535
Research Site Recruiting
Fukuoka-shi, Fukuoka-Ken, Japan, 810 8563
Research Site Recruiting
Fukuoka-shi, Fukuoka-Ken, Japan, 811 0213
Research Site Recruiting
Onga-gun, Fukuoka-Ken, Japan, 807-0051
Research Site Recruiting
Yukuhashi-shi, Fukuoka-Ken, Japan, 824-0026
Research Site Recruiting
Koriyama, Fukushima Prefecture, Japan, 963 8052
Research Site Recruiting
Gifu-shi, Gifu-Ken, Japan, 500 8717
Research Site Recruiting
Fukuyama-shi, Hiroshima-Ken, Japan, 720 0825
Research Site Recruiting
Asahikawa-shi, Hokkaido, Japan, 070 8530
Research Site Recruiting
Kobe, Hyogo Prefecture, Japan, 650-0047
Research Site Recruiting
Akashi-shi, Hyogo-Ken, Japan, 674-0064
Research Site Recruiting
Tsuchiura-shi, Ibaraki-Ken, Japan, 300 0028
Research Site Recruiting
Morioka-shi, Iwate-Ken, Japan, 020-0066
Research Site Recruiting
Kawasaki-shi, Kanagawa-Ken, Japan, 216-8511
Reseach Site Recruiting
Sendai-shi, Miyagi-Ken, Japan, 983-8520
Research Site Recruiting
Kurashiki, Okayama Prefecture, Japan, 710-8602
Research Site Recruiting
Okayama-shi, Okayama-Ken, Japan, 700-8557
Research Site Recruiting
Suita, Osaka Prefecture, Japan, 564 8565
Research Site Recruiting
Izumisano-shi, Osaka-Fu, Japan, 598 8577
Research Site Active, not recruiting
Hidaka-shi, Saitama-Ken, Japan, 350 1298
Research Site Recruiting
Fuchu-shi, Tokyo-To, Japan, 183 8524
Research Site Recruiting
Mitaka-shi, Tokyo-To, Japan, 181 8611
Research Site Recruiting
Bunkyo, Tokyo, Japan, 113 8603
Research Site Recruiting
Tanabe-shi, Wakayama-Ken, Japan, 646 8558
Research Site Recruiting
Ube-shi, Yamaguchi-Ken, Japan, 755-8505
Research Site Recruiting
Kofu-shi, Yamanashi-Ken, Japan, 400-8506
Korea, Republic of
Research Site Recruiting
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
Research Site Recruiting
Daegu, Gyeongsangnam-do, Korea, Republic of, 700-721
Research Site Recruiting
Pusan, Korea, Republic of, 602-715
Research Site Recruiting
Seoul, Korea, Republic of, 5505
Lithuania
Research Site Recruiting
Kaunas, Lithuania, 50161
Research Site Recruiting
Vilnius, Lithuania, 04130
Research Site Recruiting
Vilnius, Lithuania, 08661
Portugal
Research Site Recruiting
Almada, Portugal, 2801-915
Research Site Recruiting
Coimbra, Portugal, 3040-278
Research Site Recruiting
Lisboa, Portugal, 1349-019
Research Site Recruiting
Lisboa, Portugal, 1649-035
Research Site Recruiting
Matosinhos, Portugal, 4454-509
Research Site Not yet recruiting
Porto, Portugal, 4200-319
Research Site Recruiting
Santa Maria da Feira, Portugal, 4520-211
Russian Federation
Research Site Active, not recruiting
Kazan, Respublka Tatarstan, Russian Federation, 420061
Research Site Not yet recruiting
Krasnodar, Russian Federation, 350086
Research Site Recruiting
Moscow, Russian Federation, 119049
Research Site Recruiting
Saint Petersburg, Russian Federation, 196247
Research Site Recruiting
St. Petersburg, Russian Federation, 192242
Spain
Research Site Recruiting
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
Research Site Recruiting
Cordoba, Córdoba, Spain, 14011
Research Site Recruiting
Santiago de Compostela, La Coruña, Spain, 15706
Research Site Recruiting
Malaga, Málaga, Spain, 29010
Research Site Recruiting
Barcelona, Spain, 08003
Research Site Recruiting
Barcelona, Spain, 08035
Research Site Recruiting
Girona, Spain, 17007
Research Site Recruiting
Madrid, Spain, 28034
Research Site Recruiting
Sevilla, Spain, 41009
Research Site Recruiting
Sevilla, Spain, 41013
Research Site Recruiting
Valencia, Spain, 46026
Research Site Recruiting
Valladolid, Spain, 47003
Switzerland
Research Site Recruiting
Lugano, Ticino, Switzerland, 6900
Research Site Recruiting
Bern, Switzerland, 3010
Taiwan
Research Site Recruiting
Kaohsiung, Taiwan, 824
Research Site Recruiting
Tainan, Taiwan, 704
Research Site Recruiting
Taipei, Taiwan, 100
Research Site Recruiting
Taipei, Taiwan, 11217
United Kingdom
Research Site Recruiting
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Research Site Recruiting
London, Greater London, United Kingdom, SE5 8EF
Research Site Recruiting
London, Greater London, United Kingdom, W6 8RF
Research Site Recruiting
London, Greater London, United Kingdom, WC1N 3BG
Research Site Recruiting
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Research Site Recruiting
Glasgow, Strathclyde, United Kingdom, G51 4TF
Research Site Recruiting
Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE4 5PL
Sponsors and Collaborators
Biogen
Investigators
Layout table for investigator information
Study Director: Medical Director Biogen
Layout table for additonal information
Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT02864953    
Obsolete Identifiers: NCT04950972
Other Study ID Numbers: 252LH301
RPI 301 ( Other Identifier: Remedy Pharmaceuticals )
2017-004854-41 ( EudraCT Number )
First Posted: August 12, 2016    Key Record Dates
Last Update Posted: August 26, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Biogen:
Infarction
Cerebrovascular Disorders
Brain Diseases
Pathological Processes Necrosis
Central Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Glyburide
Hypoglycemic Agents
Physiological Effects of Drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Brain Edema
Infarction
Edema
Ischemia
Pathologic Processes
Necrosis
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Glyburide
Hypoglycemic Agents
Physiological Effects of Drugs